Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Dow 30 Stock Roundup: Apple Likely to Delay 5G iPhone Launch, Exxon Finds Oil in Pluma-1 Exploration Well

The Dow traversed a rough holiday-shortened week, marked by the return of trade war fears.

AAPL : 168.49 (-3.57%)
VZ : 57.68 (-0.69%)
QCOM : 55.99 (-1.96%)
INTC : 46.24 (-4.40%)
JNJ : 145.43 (-0.33%)
XOM : 77.64 (-0.96%)
PG : 92.45 (-1.18%)
DWDP : 53.75 (-3.88%)
Johnson & Johnson (JNJ) Stock Moves -0.08%: What You Should Know

Johnson & Johnson (JNJ) closed at $145.91 in the latest trading session, marking a -0.08% move from the prior day.

JNJ : 145.43 (-0.33%)
Global Mouthwash Market Outlook to 2023 - Key Players are Colgate-Palmolive Company, GlaxoSmithKline, Johnson & Johnson Services, Procter & Gamble and Unilever - ResearchAndMarkets.com

The "Global Mouthwash Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

JNJ : 145.43 (-0.33%)
GSK : 37.30 (-0.32%)
Watch for Johnson&Johnson to Potentially Rebound After Falling 1.27% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $144.10 to a high of $146.45. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $144.94...

JNJ : 145.43 (-0.33%)
After Yesterday's Decline of 1.27%, Johnson&Johnson Offers Investors Better Value

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $144.10 to a high of $146.45. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $144.94...

JNJ : 145.43 (-0.33%)
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

MRK : 76.72 (-2.11%)
JNJ : 145.43 (-0.33%)
ABBV : 86.96 (-3.73%)
RHHBY : 31.5000 (-0.54%)
BIP Asia Forum Opens Today

INOTF : 0.0238 (-23.23%)
PCRFY : 9.7050 (-2.95%)
JNJ : 145.43 (-0.33%)
NOK : 5.53 (-1.60%)
NSRGF : 85.9100 (+2.82%)
The St. Joe Company and Johnson & Johnson (dba Busy Bee) Announce Plans for a Busy Bee Branded Fuel Station and Convenience Store in Panama City Beach

The St. Joe Company (NYSE: JOE) ("St. Joe") and Johnson & Johnson, Inc. ("Johnson & Johnson") today announced their intent to pursue formation of a joint venture to construct, own and manage...

JOE : 14.01 (-5.91%)
JNJ : 145.43 (-0.33%)
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.

CELG : 70.08 (-3.74%)
JNJ : 145.43 (-0.33%)
ABBV : 86.96 (-3.73%)
RHHBY : 31.5000 (-0.54%)
Mylan Expands Recall of Valsartan to All Unexpired Lots

Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

MYL : 30.55 (-4.05%)
JNJ : 145.43 (-0.33%)
MRK : 76.72 (-2.11%)
TEVA : 19.41 (-4.20%)
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.

CELG : 70.08 (-3.74%)
ARWR : 13.13 (-3.67%)
JNJ : 145.43 (-0.33%)
BMY : 53.08 (-0.32%)
New Phase 3 Study Findings Show IMBRUVICA® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the National Cancer Institute (NCI)-sponsored Phase 3 study (E1912) led by the ECOG-ACRIN Research Group (ECOG-ACRIN)...

JNJ : 145.43 (-0.33%)
Darzalex (R) (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

--Data featured as a Late-Breaking Abstract at ASH 2018 (Abstract #LBA-2)

JNJ : 145.43 (-0.33%)
New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced important new data from the Phase 3 CASSINI study on the use of oral anticoagulant XARELTO® (rivaroxaban) in the management and...

JNJ : 145.43 (-0.33%)
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MAIA study demonstrating that the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone...

JNJ : 145.43 (-0.33%)
Actress, Playwright And Advocate Danai Gurira Partners With Johnson & Johnson To Help End HIV/AIDS As She Addresses Global Citizen And Visits HIV Clinical Trial In South Africa

https://mma.prnewswire.com/media/792974/Danai_Gurira_on_the_red_carpet_at_Global_Citizen_Festival.jpg

JNJ : 145.43 (-0.33%)
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 iLLUMINATE (PCYC-1130) study, which showed the combination of IMBRUVICA® (ibrutinib) plus obinutuzumab...

JNJ : 145.43 (-0.33%)
DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term results from the Phase 3 ALCYONE study showing that the addition of DARZALEX® (daratumumab) to bortezomib, melphalan...

JNJ : 145.43 (-0.33%)
Key Pharma Players With HIV Focus Ahead of World Aids Day

We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.

JNJ : 145.43 (-0.33%)
MRK : 76.72 (-2.11%)
ABBV : 86.96 (-3.73%)
GILD : 68.15 (-2.91%)
GSK : 37.30 (-0.32%)
Report: Developing Opportunities within Unifirst, Royal Caribbean Cruises, Albemarle, Tableau Software, Huami, and Johnson & Johnson -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Unifirst Corporation (NYSE:UNF),...

DATA : 123.43 (-3.55%)
HMI : 10.59 (+2.02%)
ALB : 88.65 (-2.79%)
JNJ : 145.43 (-0.33%)
RCL : 104.92 (-4.83%)
UNF : 142.63 (-1.86%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -5.10
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures saw 1 to 3 cent gains in most contracts on Friday, boosted by strong export sales data. Dec was up 2.05% on the week. This morning’s delayed weekly Export Sales update indicated that 1.177 MMT corn was purchased in the week that en...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar